Gold is 2025’s best performer. UBS sees more upside
NEW YORK - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine company with a market capitalization of $2.1 billion that maintains a strong balance sheet with more cash than debt, has announced the agenda for its upcoming Research and Development Day, which will coincide with the company’s 10-year anniversary celebration on September 8, 2025, in New York. According to InvestingPro analysis, the company’s solid financial position is reflected in its healthy current ratio of 12.39.
According to a press release statement, the event will feature presentations of new clinical data from several of the company’s oncology programs, including darovasertib in neoadjuvant uveal melanoma, IDE849 (a DLL3 TOP1 antibody-drug conjugate), and IDE397 (MAT2A). The company’s development efforts come at a crucial time, as InvestingPro data shows IDEAYA has demonstrated strong returns over the past three months, despite currently operating at a loss.
The agenda includes presentations on Phase 2 neoadjuvant uveal melanoma data for darovasertib, Phase 1 small cell lung cancer data for IDE849, and initial Phase 1 clinical data from the IDE397/Trodelvy combination in MTAP-deletion urothelial cancer.
Dr. Arun D. Singh, Director of the Department of Ophthalmic Oncology at the Cleveland Clinic’s Cole Eye Institute, will join IDEAYA’s leadership team to present data from the company’s Phase 2 trial of darovasertib and discuss the design of IDEAYA’s recently initiated Phase 3 OptimUM-10 trial.
The R&D Day will also cover the company’s IDE892 (PRMT5) program and the application of artificial intelligence and machine learning in IDEAYA’s discovery capabilities.
IDEAYA Biosciences is a precision medicine oncology company focused on developing targeted therapies for cancer. The company has built a pipeline of product candidates centered on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications.
The event will take place from 8:00 AM to 10:30 AM EST and will include a live question and answer session following the presentations. With analysts maintaining a strong buy consensus and setting price targets significantly above current levels, investors seeking deeper insights into IDEAYA’s potential can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Ideaya Biosciences has been the focus of several notable developments. Mizuho has adjusted its price target for Ideaya Biosciences, lowering it to $43 from $55, while maintaining an Outperform rating. This change follows a detailed review of Ideaya’s pipeline, which is expected to have nine clinical assets in trials by the end of 2025. Additionally, Ideaya is set to present Phase 2 data on its drug darovasertib for primary uveal melanoma at the European Society of Medical Oncology meeting in Berlin. This study involves over 90 patients and aims to highlight enucleation prevention and vision preservation.
In collaboration with Jiangsu Hengrui Pharmaceuticals, Ideaya will also present Phase 1 data on their investigational drug IDE849 for small-cell lung cancer at the World Conference on Lung Cancer. TD Cowen has initiated coverage of Ideaya Biosciences with a Buy rating, praising its robust pipeline of clinical-stage programs. Meanwhile, Goldman Sachs has resumed coverage with a Neutral rating and a $25 price target, based on a discounted cash flow analysis. These developments reflect a dynamic period for Ideaya Biosciences as it advances its clinical programs and receives varied assessments from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.